Targets › PDCD7
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.
Promotes apoptosis when overexpressed. (UniProt, Q8N8D1)
Open in Phaseline: the race on PDCD7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NextPoint Therapeutics | NPX372 B7-H7:CD3 bispecific antibody | PDCD7, CD3E | Phase 1 | Metastatic Malignant Neoplasm | Apr 2027 |
Metastatic Malignant Neoplasm (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.